Log in

American Renal Associates Stock Forecast, Price & News

+0.06 (+0.97 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $6.26
50-Day Range
MA: $6.57
52-Week Range
Now: $6.26
Volume38,722 shs
Average Volume89,974 shs
Market Capitalization$216.65 million
P/E RatioN/A
Dividend YieldN/A
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.
Read More
American Renal Associates logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified



Sales & Book Value

Annual Sales$822.52 million
Cash Flow$1.69 per share
Book Value$2.59 per share


Net Income$-13,790,000.00


Market Cap$216.65 million
Next Earnings Date11/3/2020 (Estimated)
+0.06 (+0.97 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

American Renal Associates (NYSE:ARA) Frequently Asked Questions

How has American Renal Associates' stock been impacted by COVID-19?

American Renal Associates' stock was trading at $7.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARA shares have decreased by 12.3% and is now trading at $6.26.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of American Renal Associates?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for American Renal Associates in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for American Renal Associates

When is American Renal Associates' next earnings date?

American Renal Associates is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for American Renal Associates

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings Inc (NYSE:ARA) issued its quarterly earnings data on Monday, August, 10th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.14. The business earned $205.15 million during the quarter, compared to analysts' expectations of $224.89 million. American Renal Associates had a positive return on equity of 13.79% and a negative net margin of 1.12%.
View American Renal Associates' earnings history

What price target have analysts set for ARA?

3 brokerages have issued 1 year price targets for American Renal Associates' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate American Renal Associates' share price to reach $8.67 in the next year. This suggests a possible upside of 38.4% from the stock's current price.
View analysts' price targets for American Renal Associates

Who are some of American Renal Associates' key competitors?

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include KemPharm (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA).

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the following people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 65)
  • Mr. Syed T. Kamal, Founder, Pres & Director (Age 66)
  • Mr. Mark C. Herbers, Interim CFO & Interim Chief Accounting Officer (Age 64)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 56)
  • Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.

When did American Renal Associates IPO?

(ARA) raised $161 million in an IPO on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

Who are American Renal Associates' major shareholders?

American Renal Associates' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Globeflex Capital L P (0.29%), Strs Ohio (0.24%), Bank of America Corp DE (0.12%), Jane Street Group LLC (0.08%), Goldman Sachs Group Inc. (0.07%) and Seizert Capital Partners LLC (0.07%).
View institutional ownership trends for American Renal Associates

Which major investors are selling American Renal Associates stock?

ARA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., UBS Group AG, Two Sigma Advisers LP, and American International Group Inc..
View insider buying and selling activity for American Renal Associates

Which major investors are buying American Renal Associates stock?

ARA stock was acquired by a variety of institutional investors in the last quarter, including Globeflex Capital L P, Strs Ohio, Jane Street Group LLC, Seizert Capital Partners LLC, Bank of America Corp DE, and Tsfg LLC.
View insider buying and selling activity for American Renal Associates

How do I buy shares of American Renal Associates?

Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $6.26.

How big of a company is American Renal Associates?

American Renal Associates has a market capitalization of $216.65 million and generates $822.52 million in revenue each year. The company earns $-13,790,000.00 in net income (profit) each year or $0.26 on an earnings per share basis. American Renal Associates employs 4,977 workers across the globe.

What is American Renal Associates' official website?

The official website for American Renal Associates is www.americanrenal.com.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.